Phase IIa trial of polysialylated erythropoietin (ErepoXen) in patients with chronic kidney disease who are undergoing dialysis.

Trial Profile

Phase IIa trial of polysialylated erythropoietin (ErepoXen) in patients with chronic kidney disease who are undergoing dialysis.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Dec 2014

At a glance

  • Drugs Erythropoietin (Primary)
  • Indications Anaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 02 Dec 2014 Full data analysis of the trial is expected to be completed by the end of the third quarter of 2015, according to an Aerie Pharmaceuticals media release.
    • 02 Dec 2014 Results for the second cohort are expected in the first quarter of 2015, according to a Xenetic Biosciences media release.
    • 02 Dec 2014 Dosing of the second cohort has been completed and enrolment in the third cohort has begun, according to a Xenetic Biosciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top